Laudanum are generally confined to controlling diarrhea, alleviating pain, and easing withdrawal symptoms in infants born to mothers addicted to heroin or other opioids. Recent enforcement action by the U.S. Food and Drug Administration (FDA) against manufacturers of paregoric and opium tincture suggests that opium tincture's availability in the U.S. may be in jeopardy. The terms "laudanum" and "tincture of opium" are generally interchangeable, but in contemporary medical practice the latter is used almost exclusively. Paracelsus, a 16th-century Swiss-German alchemist, experimented with various opium concoctions, and recommended opium for reducing pain. One of his preparations, a pill which he extolled as
Precision medicine As the exposome is a common concept of epidemiology, precision medicine is intertwined with molecular pathological epidemiology, which is capable of identifying potential biomarkers for precision medicine. The ability to provide precision medicine to patients in routine clinical settings depends on the availability of molecular profiling tests, e.g. individual germline DNA sequencing. While precision medicine currently individualizes treatment mainly on the basis of genomic tests (e.g. Oncotype DX), several promising technology modalities are being developed, from techniques combining spectrometry and computational power to real-time imaging of drug effects in the body. Many different aspects of precision medicine are tested in